Introduction
============

Recently, oral cavity cancer, including that of the lip, was found to be the fifteenth most common type of malignancy across populations worldwide, and the site incidence rate of oral cancer was 30.5% of all head and neck (H&N) regions (including the thyroid gland) ([@b1-ol-0-0-7562],[@b2-ol-0-0-7562]), with an incidence of 275,000 cases annually ([@b3-ol-0-0-7562]). In the 'Cancer Statistics, 2016,' 31,910 new cases of oral cancer and 6,490 deaths were estimated in the U.S. ([@b4-ol-0-0-7562]), and both of these values are 1.5-fold higher than the values in the past two decades ([@b5-ol-0-0-7562],[@b6-ol-0-0-7562]). Oral squamous cell carcinoma (OSCC) represents a majority of oral cancer cases, and the major site of occurrence is the tongue ([@b7-ol-0-0-7562],[@b8-ol-0-0-7562]). Among the OSCC cases, the rate of early-stage OSCC has increased gradually, and, to date, 67.4--80% of all OSCCs have been reported to be early-stage OSCCs ([@b9-ol-0-0-7562],[@b10-ol-0-0-7562]). Therefore, early-stage tongue squamous cell carcinoma (TSCC) is one of the most common H&N cancers ([@b1-ol-0-0-7562],[@b7-ol-0-0-7562],[@b9-ol-0-0-7562],[@b10-ol-0-0-7562]). The standard treatment of early-stage OSCC, including TSCC remains surgery, with the addition of adjuvant therapy for advanced features such as positive surgical margins and detection of venous, lymphatic, or neural invasion ([@b11-ol-0-0-7562]), which has remained relatively unchanged to date ([@b9-ol-0-0-7562]). Local recurrence and lymph node metastasis (LNM) are the main causes of death in patients with early-stage oral cancer ([@b12-ol-0-0-7562],[@b13-ol-0-0-7562]) because the relapse is generally followed by distant metastasis ([@b14-ol-0-0-7562]). The survival rate of the tumor depends on local recurrence, LNM, and distant metastasis ([@b12-ol-0-0-7562]). A relatively higher rate of neck LNM has been reported in OSCC ([@b4-ol-0-0-7562]). In particular, TSCC is well known to be associated with an increased tendency for LNM ([@b15-ol-0-0-7562]). Early stage cancer has basically good prognosis, however, the stages of OSCC have relatively poor prognoses (approximately 40% of patients died within 3 years) ([@b9-ol-0-0-7562]), and the primary reason is delayed LNM ([@b16-ol-0-0-7562],[@b17-ol-0-0-7562]). Delayed LNM is generally considered LNM that occurs after primary treatment for cancer (neck dissection was not performed during treatment) ([@b18-ol-0-0-7562],[@b19-ol-0-0-7562]). The prediction of delayed LNM is important in the treatment of early-stage oral cancer ([@b20-ol-0-0-7562]). Numerous prognostic factors (clinical, pathological, and molecular features) of LNM have been reported to date ([@b2-ol-0-0-7562],[@b9-ol-0-0-7562],[@b20-ol-0-0-7562]--[@b24-ol-0-0-7562]); however, this collectively makes daily clinical practice complex.

MicroRNAs (miRs) are expected to serve as simple markers for prognosis in cancer patients ([@b25-ol-0-0-7562],[@b26-ol-0-0-7562]). Their expressions can be easily detected in not only in fresh tissue but also blood, saliva, and formalin-fixed paraffin-embedded (FFPE) tissues ([@b27-ol-0-0-7562]--[@b30-ol-0-0-7562]). They are small (19--25 nt in length), non-coding RNAs known to critically regulate various oncogenes or tumor suppressor gene expressions ([@b31-ol-0-0-7562]--[@b35-ol-0-0-7562]). To date, more than 2,600 human miRs are present in the miRbase (Release 21), a database that stores miR data, and 60% of human protein-coding genes have been reported to be regulated by miRs ([@b36-ol-0-0-7562]). miRs play important roles in the regulation of OSCC and may serve as prognostic factors ([@b15-ol-0-0-7562],[@b37-ol-0-0-7562]--[@b40-ol-0-0-7562]). To date, many studies have investigated miR regulation in oral cancer. As a result, a plethora of miRs have been identified as prognostic factors for recurrence or metastasis in OSCC patients. There are also many pathways of cancer progression or metastasis that relate to miRs are present ([@b41-ol-0-0-7562]). Additionally, various kinds of oral cancer-related genes and pathways are present and these might be associated with tumor recurrence and metastasis ([@b3-ol-0-0-7562],[@b7-ol-0-0-7562],[@b25-ol-0-0-7562],[@b34-ol-0-0-7562],[@b41-ol-0-0-7562]--[@b43-ol-0-0-7562]). Among the miRs, miR-10a, miR-10b, miR-196a, miR-196b, and miR-615, which reside in *Homeobox* (*HOX*) gene clusters, have been the focus of much attention recently ([@b25-ol-0-0-7562],[@b44-ol-0-0-7562]--[@b46-ol-0-0-7562]). Increased regulation of *HOX* genes is associated with the proliferation and migration of OSCC cells, which can lead to recurrence or metastasis in OSCC patients ([@b45-ol-0-0-7562]). Among the five miRs, miR-615 from examination has the sparsity of studies ([@b47-ol-0-0-7562]). The remaining four miRs (miR-10a, miR-10b, miR-196a, and miR-196b) have been shown to be related to various target genes and to control many types of malignancies or other diseases ([@b34-ol-0-0-7562],[@b48-ol-0-0-7562]--[@b51-ol-0-0-7562]). In particular, some genes regulated by miR-196, impact recurrence or metastasis ([@b34-ol-0-0-7562],[@b45-ol-0-0-7562],[@b46-ol-0-0-7562],[@b52-ol-0-0-7562],[@b53-ol-0-0-7562]). Thus, miR-196 expression and functional have been investigated ([@b29-ol-0-0-7562],[@b46-ol-0-0-7562],[@b52-ol-0-0-7562],[@b54-ol-0-0-7562]). Those four miRs (miR-10a, miR-10b, miR-196a, and miR-196b) have been shown to be related with OSCC in the previous studies ([@b29-ol-0-0-7562],[@b52-ol-0-0-7562],[@b55-ol-0-0-7562],[@b56-ol-0-0-7562]). Therefore, we selected miRs as candidates in this study.

For OSCC patients, it is critically more important to identify prognostic rather than diagnostic markers. Among all malignancies, OSCC is relatively easy to detect because the oral cavity can be directly observed. However, to date, no approaches can monitor recurrence and metastasis in early-stage TSCC ([@b39-ol-0-0-7562]). Furthermore, no useful miR marker can predict recurrence or metastasis, particularly delayed LNM in patients with early-stage OSCC. Some studies have reported several miRs as prognostic markers of local recurrence or LNM; however, their data were relevant to 'all stages' and not only to the early stages of the disease ([@b57-ol-0-0-7562],[@b58-ol-0-0-7562]). Among our candidate miRs, miR-196a reportedly serves as a useful prognostic marker of 'locoregional recurrence' (local recurrence and/or regional LNM) in OSCC ([@b29-ol-0-0-7562],[@b45-ol-0-0-7562],[@b52-ol-0-0-7562]), although the cited studies focused on 'all stages' of OSCC throughout the oral cavity and did not distinguish between local recurrence and LNM. To examine local recurrence or delayed LNM, only LNM after treatment should be investigated. Moreover, there are few studies on miR expression in early-stage OSCC ([@b10-ol-0-0-7562],[@b59-ol-0-0-7562],[@b60-ol-0-0-7562]). We hypothesized that the above-mentioned miRs could be useful prognostic markers of early-stage TSCC. For testing this hypothesis, we used reverse transcription-quantitative polymerase chain reaction (RT-qPCR) to analyze the expression of the miRs in FFPE tissues of patients with early-stage TSCC compared the findings with those of adjacent normal tissue (ANT) in order to determine the relationship between miR expressions and disease features.

Materials and methods
=====================

### Patients and tissue samples

Informed consent was obtained from all patients. The Ethics Committee of the University of the Ryukyus (Okinawa, Japan) approved this study on June 22, 2016 (approval no. 957), and the study complied with the Declaration of Helsinki. The Conflict of Interest Committee of the University of the Ryukyus approved this study on June 22, 2016, and the authors have no conflicts of interest to disclose. Samples of cancer tissue and ANT were retrospectively collected from 50 patients with primary early-stage TSCC (cT1T2N0) clinically (excluding cancer *in situ*, dysplasia, pre-cancer diseases, and verrucous carcinoma), who were aged ≥20 years and diagnosed by our department. All patients underwent surgical excision between January 2005 and December 2014. All cancers were located on the mobile tongue. Some cases were from our previous retrospective study ([@b61-ol-0-0-7562]), whose aim was to compare patients who underwent surgery alone to those with neoadjuvant chemotherapy and surgery. The current study excluded patients who underwent neoadjuvant therapy. Therefore, no methods or results from the previous study were included in the current study.

No LNM or distant metastasis was confirmed by assessing clinical symptoms and radiological lesions before surgery. All alive patients were followed for ≥2 years after treatment, which is considered an appropriate timeframe to evaluate recurrence or metastases ([@b17-ol-0-0-7562],[@b62-ol-0-0-7562]). The maximum length of follow-up was 5 years ([@b63-ol-0-0-7562]). We excluded the following patients: i) who received chemotherapy, radiotherapy, or both before surgery; ii) who underwent simultaneous neck dissections (in all patients, no LNM was suspected clinically or radiologically; therefore, LNM after curative surgery could be defined as 'delayed' LNM); iii) two or more additional resections on the day after the first local resection because of positive margins; iv) who had coexisting cancer; and v) patients with a history of H&N cancers or those who underwent treatment for these tumors.

The surgical margins used were ≥10 mm clinically for all patients; thus, the resection margins of all tumors were microscopically free of cancer cells. In three cases with closed surgical margins, tumors were pathologically found a few days after surgery, and adjuvant chemotherapy (oral therapy of S-1) was administered. No patient received adjuvant radiotherapy. All stained tissues were reviewed by pathologists at the Department of Pathology, University Hospital of the Ryukyus. Histological grades were classified by pathologists according to the WHO guidelines ([@b64-ol-0-0-7562]) as well, moderate, or poor. There was no undifferentiated type. The mode of invasion was divided into four main grades (1, 2, 3, and 4C/4D) by using the criteria proposed by Yamamoto *et al*. for hematoxylin and eosin specimens ([@b65-ol-0-0-7562]). Lymphatic, venous, and neural invasions were evaluated with immunohistochemical stains or special stains, including D2-40 (code M3619; Dako, Glostrup, Denmark), Victoria blue (no. 4077; Muto Pure Chemical Co., Ltd., Tokyo, Japan), and S-100 (cat. no. Z0311; Dako), respectively. Tumor depth was measured vertically between the adjacent normal mucosa surface and the deepest point of tumor invasion ([@b66-ol-0-0-7562]). All stained slides were 3-µm thick and were obtained from surgical specimens. Patient history of alcohol use or smoking was determined. No patient chewed betel quid, which is a high-risk factor for oral cancer. The definitions of recurrence/metastasis were as follows: i) local recurrence: lesions appearing in the oral cavity and nearly where resection for tongue cancer was performed between 6 weeks and 5 years after the first curative surgery; ii) LNM: lesions appearing only in the neck lymph node region between 6 weeks and 5 years after the first curative surgery; and iii) distant metastasis: distant lesions appearing between 6 weeks and 5 years after the first curative surgery ([@b63-ol-0-0-7562]). In the present study, no combination of local recurrence or LNM was found. At the time of diagnosis, distant metastases, local recurrence, or LNM was not found. Overall survival (OS) was defined as the time from the date of surgical excision to the date of death or last follow-up. Local recurrence-free survival (LRFS), LNM-free survival (LNMFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS) were defined as the time from the date of surgical excision to the date of local recurrence, LNM, distant metastasis, and any recurrence or metastasis, respectively, or the last follow-up day, including death without recurrence.

### Collection of target samples from FFPE tissues using laser-capture microdissection (LMD)

FFPE tissues acquired from surgical excisions or biopsies were collected for analysis. Before performing LMD, pathologists classified the cancer and ANT areas. ANTs were defined as epithelial tissues located on the surgical margin that were ≥5 mm away from cancer tissues. A microtome (Leica RM2235; Leica Biosystems Nussloch GmbH, Nussloch, Germany) was used to prepare 7-µm-thick tissue sections from FFPE tissue blocks, which were placed on nuclease-free 1.0 PEN Membrane Slides (no. 415190-9081-000; Zeiss GmbH, Jena, Germany). Then, tissue sections were deparaffinized, stained with cresyl violet, and dried in air briefly, and the slides were subsequently stored at −20°C. LMD was performed using a Zeiss PALM Microbeam laser microdissection system (Carl Zeiss Microscopy, Jena, Germany) and PALM Robo v4.6 software. For capturing tissue, Adhesive Caps (no. 415190-9201-000; Zeiss GmbH) were used. Tissue sections (cancer tissue and paired ANT) were immediately deparaffinized and total RNA was then extracted.

### RT-qPCR

Total RNA was extracted from FFPE tissues using an miRNeasy FFPE kit (Qiagen GmbH, Hilden, Germany) ([@b67-ol-0-0-7562]), which involved removal of genomic DNA contamination and RNA purification with RNeasy MinElute. The sample was stored at −80°C before use for reverse transcription (RT). The purity of total RNA was examined using BioSpec-nano (Shimadzu, Kyoto, Japan). RT was performed using a Taqman microRNA RT kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA) ([@b68-ol-0-0-7562]) with 5 µl of total RNA, and cDNA samples were stored at −20°C before use. We selected miR-196a-3p to evaluate miR-196a-2. TaqMan miRNA assays (Thermo Fisher Scientific, Waltham, Inc.) were used to assess the relative expressions of the following five miRs: miR-10a (miR-10a-5p: assay ID 000387, mature miR sequence: UAC CCU GUA GAU CCG AAU UUG UG), miR-10b (miR-10b-5p: assay ID 002218, mature miR sequence: UAC CCU GUA GAA CCG AAU UUG UG), miR-196a-5p (assay ID 241070_mat, mature miR sequence: UAG GUA GUU UCA UGU UGU UGG G), miR-196a-3p (assay ID 002336, mature miR sequence: CGG CAA CAA GAA ACU GCC UGAG), and miR-196b (miR-196b-5p: assay ID 002215, mature miR sequence: UAG GUA GUU UCC UGU UGU UGG G), according to the manufacturer\'s instructions. The reactions were carried out at 50 °C for 2 min and at 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec and at 60°C for 60 sec. All experiments were carried out in triplicate. Data were analyzed with the 2^−ΔΔCq^ method ([@b69-ol-0-0-7562]). Data were normalized using small nuclear RNAs 44 and 48 (RNU44, assay ID 001094; RNU48, assay ID 001006; Thermo Fisher Scientific, Inc.) as endogenous controls. In all 50 patients, RNU44 and 48 could be determined. The undetermined Cq value of the other five miRs (miR-10a, miR-10b, miR-196a-5p, miR-196a-3p, and miR-196b) was estimated as 40 Cq ([@b70-ol-0-0-7562],[@b71-ol-0-0-7562]). The formulas were as follows: ΔCq (cancer) value=(Cq value of cancer tissue)-(the average Cq value of RNU44 and RNU48); ΔCq (normal) value=(Cq value of normal tissue)-(the average Cq value of RNU44 and RNU48); and ΔΔCq value=ΔCq (cancer) value-ΔCq (normal) value. A lower ΔCq value represented higher expression of miR. A lower ΔΔCq value represented higher expression of miR in cancer tissues than in paired ANTs of the same patient.

### Statistical analysis

The Gaussian distribution of each group was tested using Shapiro-Wilk test. The homogeneity of variances was confirmed using the Levene test. For data with a Gaussian distribution, the difference between two groups was demonstrated using the Student\'s t-test or the Welch\'s t-test, depending on the homogeneity of the variances. For data that did not conform to a Gaussian distribution, the Mann-Whitney *U* test was applied. When analyzing three or more subgroups, one-way ANOVA or the Kruskal-Wallis test was used to assess whether the data conformed to a Gaussian distribution. The association of the ΔCq value between early-stage TSCC tissue and paired ANT was confirmed using a paired t-test. The ΔΔCq values and the clinicopathological characteristics of the patients were evaluated using the tests mentioned above. Differences in the patient numbers between high and low ΔΔCq value regulation groups were evaluated using a two-tailed Fisher\'s exact test. Survival analyses (OS, LRFS, LNMFS, DMFS, and DFS) were performed using the Kaplan-Meier method, and survival curves were compared using the log-rank test. A receiver operating characteristic (ROC) curve analysis was performed and area under the ROC curve (AUC) was determined to examine the feasibility of using the ΔΔCq value as an approach for assessing the prognosis of delayed LNM and the mode of tumor invasion. Youden index was calculated for the identification of the best ΔΔCq cut-off value. P\<0.05 was considered to indicate statistical significance. All statistical analyses were performed using JMP software (JMP Version Pro 12; SAS Institute Inc., Cary, NC, USA).

Results
=======

### Characteristics

[Table I](#tI-ol-0-0-7562){ref-type="table"} presents the characteristics of the patients. The numbers of patients with local recurrence, delayed LNM, and distant metastasis were 4, 17, and 3, respectively. All distant metastases occurred after treatment and control of delayed LNM. The clinical T stage was cT1 in 32 patients and cT2 in 18 patients. The histological grade was G1/well in 31 patients, G2/moderate in 16 patients, and G3/poor in 1 patient. The mode of tumor invasion was 1--3 in 39 patients and 4C-4D in 11 patients. The depth of the tumor was \<5 mm in 42 patient and between 5 and 10 mm in eight patients. Lymphatic, venous, and neural invasions were found in six, five, and five patients, respectively. Nineteen patients were current or past smokers and 22 were current or past alcohol drinkers.

### All 5 miRs were significantly expressed in early-stage TSCC tissues

The levels of all five candidate miRs showed significant differences between early-stage TSCC tissues and ANTs, and P-values for miR-196a-5p, miR-196b, miR-10a, miR-10b, and miR-196a-3p were \<0.001, \<0.001, \<0.001, \<0.001, and 0.003, respectively ([Fig. 1A-E](#f1-ol-0-0-7562){ref-type="fig"}). miR-196a-5p and miR-196b were upregulated ([Fig. 1A and B](#f1-ol-0-0-7562){ref-type="fig"}) while miR-196a-3p, miR-10a, and miR-10b were downregulated in early-stage TSCC tumors ([Fig. 1C-E](#f1-ol-0-0-7562){ref-type="fig"}). Thus, all five miRs were viable biomarkers.

### Clinicopathological significance of miR levels in early-stage TSCC

We analyzed the association between miR expression (using ΔΔCq values) and clinicopathological parameters ([Table II](#tII-ol-0-0-7562){ref-type="table"}). For several characteristics, the P-values were significant. The ΔΔCq values of miR-196a-5p and miR-196a-3p were significantly different between the local recurrence and no recurrence groups. The ΔΔCq values of miR-196a-5p and miR-196a-3p were also significantly different between the delayed LNM and no LNM groups. In the distant metastasis subgroup, the ΔΔCq values of miR-196b were significantly different. Furthermore, in the sex, clinical stage, mode of tumor invasion, depth of tumor, and smoking subgroups, the ΔΔCq values of miR-10b, miR-196b, miR-196a-5p, miR-196a-3p, and miR-10b, respectively, were significantly different. In contrast, there was no significant relationship between miRs levels and age, alcohol intake, and other pathological features such as histological grade, venous/lymphatic invasion, or neural infiltration ([Table II](#tII-ol-0-0-7562){ref-type="table"}). We assessed the most appropriate biomarker candidates. As described above, miR-196a-5p and miR-196b were upregulated ([Fig. 1A and B](#f1-ol-0-0-7562){ref-type="fig"}) while miR-196a-3p, miR-10a, and miR-10b were downregulated in early-stage TSCC tissues than in ANTs ([Fig. 1C-E](#f1-ol-0-0-7562){ref-type="fig"}). We thought that miR-196a-5p (local recurrence), miR-196a-3p (LNM), miR-196b (distant metastasis), and miR-10b (smoking) were not appropriate markers because some combinations of the subgroups and ΔΔCq values were controversial. Further, miR-10b (gender) and miR-196b (clinical, stage) were not appropriate markers because these can be confirmed clinically. On the other hand, we thought that miR-196a-5p (LNM and mode of tumor invasion) and miR-196a-3p (local recurrence) were appropriate candidates because the expressions were consistent.

### Association between miR-196a-5p levels and LNMFS in patients with early-stage TSCC

We divided patients using the median ΔΔCq value as the cut-off value. On comparing the low miR-196a-5p ΔΔCq value regulation (i.e., high expression of miR-196a-5p) group and the high regulation group, no bias was found except with regard to delayed LNM ([Table III](#tIII-ol-0-0-7562){ref-type="table"}). Thus, miR-196a-5p could be a prognostic marker. In contrast, on comparing the low miR-196a-3p ΔΔCq value regulation (i.e., high expression of miR-196a-3p) group and the high regulation group, bias was found for delayed LNM and depth of tumor (data not shown). Thus, miR-196a-3p could not be considered as a prognostic marker of 'local recurrence' because of the biases. The Kaplan-Meier analysis of each survival curve \[OS, LRFS, LNMFS, DMFS, and DFS ([Fig. 2A-E](#f2-ol-0-0-7562){ref-type="fig"}, respectively)\] indicated that LNMFS was shorter in the low miR-196a-5p ΔΔCq value regulation (i.e., higher regulation in TSCC tissues than in ANTs) group than in the high regulation group (P=0.0079) ([Fig. 2C](#f2-ol-0-0-7562){ref-type="fig"}). In contrast, OS, LRFS, DMFS, and DFS showed no significant differences (P=0.6205, 0.0502, 0.5382, and 0.1049, respectively) ([Fig. 2A, B, D and E](#f2-ol-0-0-7562){ref-type="fig"}). In subsequent ROC analysis, ΔΔCq values revealed that miR-196a-5p levels yielded P=0.0025, an AUC of 0.740 and a cut-off value of −0.875 to distinguish delayed LNM ([Fig. 3A](#f3-ol-0-0-7562){ref-type="fig"}). According to the result presented in [Table II](#tII-ol-0-0-7562){ref-type="table"}, the mode of tumor invasion was also evaluated by ROC analysis. ΔΔCq values revealed that miR-196a-5p levels yielded P=0.0133, an AUC of 0.718 and a cut-off value of −0.74 to distinguish YK grade 4C-4D from YK grade 1--3 ([Fig. 3B](#f3-ol-0-0-7562){ref-type="fig"}).

Discussion
==========

Our study illustrates two important clinical issues. First, to the best of our knowledge, this is the first study to examine LNM-related miR in early-stage TSCC and is the first miR study of delayed LNM of H&N cancer. Second, miR-196a-5p was significantly upregulated in early-stage TSCC. In addition, miR-196a-5p upregulation increased the risk of delayed LNM and was associated with a shorter LNMFS rate in early-stage TSCC.

We searched the literature from 1993 ([@b72-ol-0-0-7562]) to 2017 using PubMed and Google Scholar; however, no reports on LNM-related miRs in early-stage TSCC or miR studies on delayed LNM of H&N cancer were found. Identification of a useful prognostic marker of LNM is an urgent issue in cancer patients who are not only in the advanced stage but also in the early stage.

We focused on delayed LNM for three reasons. First, in general, early-stage OSCC patients have relatively good prognosis when compared to that in advanced-stage patients ([@b73-ol-0-0-7562]). Fundamentally, early-stage tongue cancer is less likely to result in the distant metastasis ([@b14-ol-0-0-7562]), which is consistent with our finding; however, delayed LNM worsens the prognosis ([@b16-ol-0-0-7562]) because LNM is generally followed by distant metastasis ([@b14-ol-0-0-7562]), which is similar to the findings in our cases. In our study, all distant metastasis cases occurred after delayed LNM. Second, the treatment of early-stage OSCC is still controversial with regard to whether elective neck dissections (ENDs) can be performed ([@b11-ol-0-0-7562],[@b74-ol-0-0-7562],[@b75-ol-0-0-7562]), even after a report by D\'cruz *et al* ([@b76-ol-0-0-7562]) that described the importance of ENDs in early-stage OSCC to improve the survival rate. However, the current guideline of The National Comprehensive Cancer Network ([@b11-ol-0-0-7562]) does not strongly define END as the standard therapy for early-stage oral cancer. Finally, to evaluate the treatment results without performing END, it is important to clearly distinguish 'delayed' LNM from 'simultaneous' LNM ([@b20-ol-0-0-7562]).

miR can be reliable markers in daily cancer treatment. Many markers of cancer recurrence or metastasis have been reported (including those described in the new guidelines of the Union for International Cancer Control ([@b2-ol-0-0-7562])) and are in use currently. This tends to make the clinician rather uncertain because the markers are too many to use in daily practice. In a recent review, Yu *et al* reported that no current clinical or pathological tools that are useful for monitoring recurrence or metastasis in early-stage OSCC patients ([@b39-ol-0-0-7562]). On the other hand, Irani recently suggested that 'the mode of tumor invasion' is important as a prognostic factor for LNM ([@b77-ol-0-0-7562]). Based on our results ([Table I](#tI-ol-0-0-7562){ref-type="table"}), we conclude that pathological properties such as mode of tumor invasion, depth of tumor, venous/lymphatic invasion, and neural infiltration can be rarely observed in such early-stage cases ([@b16-ol-0-0-7562],[@b78-ol-0-0-7562]). Additionally, a relatively high rate of well-differentiated tumors was found among our patients, which is not rare and is consistent with a previous finding in a study by Yanamoto *et al* ([@b63-ol-0-0-7562]). Only 'the mode of tumor invasion' appeared to be a prognostic factor of delayed LNM according to our results ([Table III](#tIII-ol-0-0-7562){ref-type="table"}, [Fig. 3B](#f3-ol-0-0-7562){ref-type="fig"}). In contrast, targeted miRs could be evaluated by RT-qPCR and were significantly regulated in cancers from patients with delayed LNM when compared to those from patients without LNM in our study. As mentioned above, in the daily practice of OSCC treatment, a potential marker to predict delayed LNM before or immediately after treatment is strongly desired. miR is a useful approach that can easily detect the presence of OSCC not only in fresh tissues but also in blood, saliva, and FFPE tissues ([@b27-ol-0-0-7562]--[@b30-ol-0-0-7562]).

When selecting a miR, we suggest that it is important to confirm how many oncogenes or tumor suppressor genes with solid evidence are targeted by that miR. Three reasons for the above suggestion have been presented. First, miRs are often differentially expressed in different cancer conditions such as cancer cells *in vitro*, tissues *in vivo*, and human tissues. The functions of miRs are associated with their up- or downregulation ([@b39-ol-0-0-7562]) and their expression affect several target genes. Many miRs have been reported to be expressed in OSCC ([@b15-ol-0-0-7562],[@b39-ol-0-0-7562]); however, controversially, one study reported that certain miRs were significantly more upregulated in cancer tissues or cells than in normal tissues or cells ([@b39-ol-0-0-7562]). In contrast, it was reported that these miRs were downregulated in other cancer tissues or cells ([@b39-ol-0-0-7562]). For example, miR-148b is upregulated in TSCC cell lines ([@b79-ol-0-0-7562]) but downregulated in Syrian hamster OSCC ([@b80-ol-0-0-7562]). Similarly, miR-197 was found to be strongly upregulated in LMD of human TSCC ([@b81-ol-0-0-7562]) but downregulated in human TSCC cell lines ([@b79-ol-0-0-7562]). Second, one particular miR targets thousands of messenger RNAs (mRNAs); in contrast, one mRNA can be targeted by hundreds of different miRs ([@b31-ol-0-0-7562]), which contiguously affects several pathways of tumor processes through mRNA ([@b30-ol-0-0-7562]). Thus, complicated pathways of cancer initiation or progression exist ([@b25-ol-0-0-7562],[@b82-ol-0-0-7562]). Moreover, cancer progression itself has a multistep process associated with multiple alterations of oncogenes and tumor suppressor genes involving miR functions ([@b31-ol-0-0-7562]). Thus, many miRs are reported as candidates of potential clinical utility, including LNM with OSCC ([@b39-ol-0-0-7562],[@b83-ol-0-0-7562]--[@b86-ol-0-0-7562]). Third, there are a plethora of miRs related to LNM in OSCC of human patients, *in vivo* or *in vitro*, including *let-7d* ([@b77-ol-0-0-7562]), *let-7g* ([@b87-ol-0-0-7562]), miR-17 and miR-20a ([@b88-ol-0-0-7562]), miR-21 ([@b89-ol-0-0-7562]), miR-26b ([@b90-ol-0-0-7562]), miR-29b ([@b91-ol-0-0-7562]), miR-31 ([@b92-ol-0-0-7562]), miR-34a ([@b93-ol-0-0-7562]), miR-93 ([@b94-ol-0-0-7562]), miR-134 ([@b95-ol-0-0-7562]), miR-138 ([@b84-ol-0-0-7562]), miR-153 ([@b96-ol-0-0-7562]), miR-155-5p ([@b97-ol-0-0-7562]), miR-181 ([@b98-ol-0-0-7562]), miR-196a/b ([@b52-ol-0-0-7562]), miR-203 ([@b99-ol-0-0-7562]), miR-205 ([@b83-ol-0-0-7562]), miR-211 ([@b100-ol-0-0-7562]), miR-214-3p ([@b10-ol-0-0-7562]), miR-222 ([@b101-ol-0-0-7562]), miR-363 ([@b102-ol-0-0-7562]), miR-372 and miR-373 ([@b85-ol-0-0-7562]), miR-375 ([@b10-ol-0-0-7562]), miR-376c-3p ([@b86-ol-0-0-7562]), miR-491-5p ([@b103-ol-0-0-7562]), miR-1246 ([@b104-ol-0-0-7562]), miR-1275 ([@b105-ol-0-0-7562]). However, no reports have evaluated only 'delayed' LNM of OSCC. In addition, no report has described LNM of early-stage TSCC. Therefore, when choosing miR for a study, we suggest that it is important to confirm how many oncogenes or tumor suppressor genes with solid evidence are targeted by the miR. Among so many miRs related to LNM, we focused on the following *HOX* gene-related miRs ([@b44-ol-0-0-7562]--[@b46-ol-0-0-7562],[@b52-ol-0-0-7562]): miR-10a, miR-10b, miR-196a, miR-196b, and miR-615. Those miRs are within the *HOX* gene clusters that are related to functions of many types of H&N cancers ([@b44-ol-0-0-7562]--[@b46-ol-0-0-7562]).

*HOX* genes are cancer development genes and tend to differ with regard to their up- or downregulation depending on the cancer site or type ([@b106-ol-0-0-7562]). *HOX* genes are suggested to be dysregulated in human OSCC ([@b107-ol-0-0-7562]). In oral cancer cells or tissues, many *HOX* genes are upregulated ([@b45-ol-0-0-7562]). *HOX* genes are reported as oncogenes that regulate epithelial-mesenchymal transition, cancer invasion, and apoptotic pathways ([@b45-ol-0-0-7562]). Upregulation of particular *HOX* genes is associated with upregulation of miRs within each *HOX* gene. The miRs: miR-10, miR-196, and miR-615 are present within four types of *HOX* gene clusters: miR-10a and miR-196a-1 are located in *HOXB* on chromosome 17, miR-10b is located in *HOXD* on chromosome 2, miR-615 and miR-196a-2 are located in *HOXC* on chromosome 12, and miR-196b is located in *HOXA* on chromosome 7 ([@b45-ol-0-0-7562],[@b46-ol-0-0-7562],[@b108-ol-0-0-7562]). miR-196a generally means miR-196a-5p. miR-196a-1 and miR-196a-2 have the same sequence; however, they are located on different chromosomes ([@b34-ol-0-0-7562]). We selected miR-196a-3p (miR passenger strand of miR-196a-2; not present in miR-196a-1) because we attempted to compare the functions of miR-196a-1 and miR-196a-2 ([@b29-ol-0-0-7562],[@b34-ol-0-0-7562]). miR-615 is not reported to be related to cancer ([@b46-ol-0-0-7562]); therefore, we excluded miR-615 from examination as a prognostic marker because of the sparsity of studies. miR-10a and miR-10b have not been reported to be related to LNM of OSCC to date. However, miR-10 s have been shown to be associated with cancer metastasis. miR-10a was reported to regulate metastasis in various types of cancer ([@b109-ol-0-0-7562]) and to contribute to LNM of gastric cancer ([@b110-ol-0-0-7562]), while miR-10b was reported to be significantly upregulated in OSCC cell lines and to promote cell migration and invasion ([@b56-ol-0-0-7562]). We eventually selected five miRs (miR-10a, miR-10b, miR-196a-5p, miR-196a-3p, and miR-196b) as candidate prognostic markers. In our study, the levels of all five candidate miRs were significantly regulated in cancer tissues when compared to ANTs. This confirmed their possible utility as markers of early-stage TSCC. In our subsequent analyses, we found that miR-196a-5p was a possible prognostic marker of delayed LNM in early-stage TSCC.

In a recent study, significant miR-196a-5p upregulation was observed in early-stage TSCC tissues. Furthermore, miR-196a-5p upregulation increased the risk of delayed LNM and was especially associated with a shorter LNMFS rate in early-stage TSCC. Indeed, our study is not the first to report that miR-196a-5p upregulation is associated with OSCC metastasis ([@b29-ol-0-0-7562],[@b52-ol-0-0-7562]), and we needed previous evidence to rationalize our study of miR-196a-5p. Liu *et al* reported that miR-196a was significantly upregulated in tumor tissues and plasma in 'all stages' of OSCC ([@b29-ol-0-0-7562]), suggesting that it might serve as a diagnostic and prognostic marker of LNM. In contrast, we investigated only prognostic markers because diagnostic markers are less important as OSCC is particularly easy to detect clinically. We also limited the study to patients with early-stage TSCC for four reasons. First, miR expression in cancer tissue is specific to site or cancer type. miRs expressed in the tongue and in other sites of the oral cavity differ ([@b26-ol-0-0-7562]). Furthermore, Harris *et al* reported that the expression of most miRs was different in three sites of the H&N region via microarray analysis of human SCC tissue ([@b111-ol-0-0-7562]). Moreover, miRs expressions of H&N SCC were different compared to those of H&N ACC using microarray analysis ([@b112-ol-0-0-7562]). Second, miR expression can be different between early-stage and advanced-stage cancer, and this has been reported previously in microarray studies ([@b58-ol-0-0-7562],[@b89-ol-0-0-7562]). Despite being the same type of cancer, early-stage and advanced-stage OSCCs showed significantly different miR-31 expression levels ([@b92-ol-0-0-7562]). Other studies reported distinct expression modes in oral cancer and premalignant disease (such as dysplasia and leukoplakia) ([@b113-ol-0-0-7562],[@b114-ol-0-0-7562]). The expressions of some genes are distinct between oral carcinoma *in situ* and early-stage OSCC ([@b115-ol-0-0-7562]). Therefore, OSCC appears and progresses by complicated multi-stage processes ([@b39-ol-0-0-7562],[@b116-ol-0-0-7562]). Thus, we suggest that early-stage and advanced-stage TSCC have different miRs impacting and regulating pathways. Furthermore, we excluded premalignant disease and carcinoma *in situ* in the current study. Third, as mentioned above, early-stage TSCC is one of the most common H&N cancers, and TSCC is the most aggressive type of OSCC ([@b21-ol-0-0-7562]). Fourth, it is relatively easy in early-stage OSCC to distinguish neck LNM from local recurrence. In contrast, it is often difficult to classify advanced cancer as one or another relapse, especially after neck dissection ([@b117-ol-0-0-7562]). We speculate that limiting our study to early-stage TSCC helped to effectively evaluate only delayed LNM or local recurrence and tumor-specific miRs.

miR-196a-5p targets several *HOX* genes ([@b35-ol-0-0-7562],[@b118-ol-0-0-7562]) and directly targets many other genes ([@b35-ol-0-0-7562]). Lately, it has been reported that miR-196-5p is aberrantly expressed in many kinds of cancers and targets many genes, including several genes of the *HOX* family, and functions, such as cancer proliferation, metastasis, and invasion ([@b34-ol-0-0-7562],[@b46-ol-0-0-7562]). miR-196a-5p is upregulated in OSCC tissues and cells, and its inhibition of mRNA translation contributes to many cancer processes (cell proliferation, migration, and invasion), as an oncogene ([@b29-ol-0-0-7562],[@b35-ol-0-0-7562],[@b52-ol-0-0-7562]). A certain *HOX* gene upregulation indicates miRs located in the *HOX* gene. Therefore, cancer progression by *HOX* gene upregulation as an oncogene is related to miR-196a-5p upregulation in H&N SCC ([@b45-ol-0-0-7562]). Furthermore, *HOX* genes are related to *HOTAIR* ([@b119-ol-0-0-7562],[@b120-ol-0-0-7562]), which exists upstream of miR-196a-2 and has been reported to be highly regulated in OSCC and significantly upregulated in cancers with LNM when compared to the regulation in cancers without metastasis ([@b35-ol-0-0-7562],[@b121-ol-0-0-7562]). As an oncogene of H&N cancer and oral cancer, miR-196-5p targets many genes, as described above ([@b34-ol-0-0-7562],[@b35-ol-0-0-7562]). *Annexin A1* is targeted by miR-196a-5p over-regulation and is related to metastasis as well as proliferation, invasion, and radio resistance of H&N cancer ([@b53-ol-0-0-7562]). *NME4* was directly inhibited by miR-196a-5p with significant upregulation in cancer tissues and was correlated with neck LNM of oral cancer ([@b52-ol-0-0-7562]). *MAMDC2* has been reported as a novel direct target of miR-196a-5p in H&N SCC ([@b46-ol-0-0-7562]). All the above-mentioned genes are regulated and caused LNM by upregulation of miR-196a-5p, which is similar to our results. Based on the results of our study, miR-196a-5p can be a potential prognostic marker of delayed LNM. In addition, future studies are required to confirm whether miR-196-5p can be used as a therapeutic marker for OSCC metastasis, as reported by Chen *et al* ([@b35-ol-0-0-7562]).

The use of a biomarker for diagnosis or prognosis of cancer is a general concept ([@b3-ol-0-0-7562]). Several molecular markers (e.g., protein, mRNA, and miR) have been studied by using tissue, blood, and saliva ([@b113-ol-0-0-7562]). However, a reliable biomarker that can detect cancer early, provide a more accurate diagnosis, predict prognosis, and allow the patient to receive the best treatment is strongly desired ([@b113-ol-0-0-7562]). As described above, for OSCC patients, it is critically more important to identify prognostic markers than diagnostic markers. To establish a miR as a biomarker with a highly reliable assay system for routine clinical purposes, four conditions are needed. One, the examination of the biomarker should be easy and the method should be reproducible for clinical use ([@b122-ol-0-0-7562]). Two, many examination cases are needed ([@b10-ol-0-0-7562],[@b54-ol-0-0-7562]). Three, noninvasive methods should be preferred ([@b123-ol-0-0-7562]). Four, tissues should be accurately collected ([@b122-ol-0-0-7562]). Moreover, as described above, we should pay attention to the characteristics of the miRs. The biomarker should be specific for early-stage TSCC and not for other H&N cancers because miR expression is stage- and site-specific, as well as cancer-specific ([@b26-ol-0-0-7562],[@b92-ol-0-0-7562],[@b111-ol-0-0-7562],[@b112-ol-0-0-7562]). In the current study, the tissues of patients were accurately collected, and there were epithelial tumor tissues and epithelial ANTs collected by LMD ([@b81-ol-0-0-7562]). The FFPE examination was noninvasive, and it is relatively easy to increase the number of cases than other type of samples. On the other hand, fresh tissue was collected with an invasive (scalpel) method and, sometimes, epithelial tissues were collected along with stroma tissues, making the examination results uncertain ([@b122-ol-0-0-7562]). In the future, we plan to confirm the current results in a prospective study. Recently, Adami *et al* reported the advantages of brush biopsy (noninvasive) of oral cancer ([@b122-ol-0-0-7562]). This method allows easy assessment of the difference in OSCC tissue and epithelial ANT for pretreatment timing ([@b124-ol-0-0-7562]), and accumulation of cases is strongly expected in the future ([@b123-ol-0-0-7562]).

ROC analysis is a standard approach to identify a detection cut-off for a disease biomarker ([@b125-ol-0-0-7562]). In ROC analysis, the AUC can be calculated to evaluate the power of an assay system to accurately distinguish between true and false results for diseases, especially cancer ([@b125-ol-0-0-7562],[@b126-ol-0-0-7562]). As used by many researchers, the AUC scale was defined by Hosmer *et al* ([@b127-ol-0-0-7562]): if AUC=0.5, no discrimination; if 0.5\<AUC\<0.7, poor discrimination; if 0.7≤AUC\<0.8, acceptable discrimination; if 0.8≤AUC\<0.9, excellent discrimination; and if AUC≥0.9, discrimination is considered. Based on our results, miR-196-5p can be a potential prognostic marker. In our ROC analysis, our results were statistically significant according to the findings of previous studies on biomarkers ([@b126-ol-0-0-7562],[@b128-ol-0-0-7562],[@b129-ol-0-0-7562]) (P\<0.05 and AUC\>0.7).

miR is a useful marker that can easily detect the expression of OSCC not only in fresh tissues but also blood, saliva, and FFPE tissues ([@b27-ol-0-0-7562]--[@b30-ol-0-0-7562]). Among these tissues, FFPE tissues are useful to evaluate miR expressions ([@b57-ol-0-0-7562],[@b58-ol-0-0-7562],[@b130-ol-0-0-7562]). Very old FFPE tissues, such as those obtained 10--19 years previously, have been used in miR study ([@b28-ol-0-0-7562],[@b131-ol-0-0-7562],[@b132-ol-0-0-7562]). Therefore, we could use old tissue for evaluation, with the oldest sample being 12 years old. Certainly, our total RNA amount and density were low by using BioSpec-nano; however, in all patients, the Cq values of RNU44 and RNU48 could be determined (Cq values=23.4--36.58) for use. mRNA in FFPE tissues is difficult to examine using the above method because formalin fixation reduces the recovery and quality of RNA ([@b131-ol-0-0-7562]). In contrast, miR in FFPE tissues can be examined because miRs are small and are protected by the RISC complex ([@b133-ol-0-0-7562]). miRs in FFPE tissues are reportedly robust and well-regulated in RT-qPCR and frozen tissue sample ([@b131-ol-0-0-7562]). FFPE tissues are valuable for conducting retrospective studies of human cancer ([@b131-ol-0-0-7562]). Therefore, many miR studies using FFPE can be accumulated in the future.

The present study has some limitations. First, the results of the present study might be limited because of the retrospective study design and inclusion of only 50 patients. Additionally, fresh tissues were not analyzed. However, the number of patients appeared to be sufficient according to previous studies ([@b83-ol-0-0-7562]--[@b85-ol-0-0-7562],[@b134-ol-0-0-7562],[@b135-ol-0-0-7562]). Further studies that assess fresh cancer tissues and include a higher number of patients should be performed. Second, the study was biased as it investigated only miR-10a, miR-10b, miR-196a-5p, miR-196a-3p, and miR-196b. Third, differential expression did not allow identification of regulatory mechanisms, particularly when the activities/expressions of the targets/pathway output were not investigated. We suggest that one miR repressed many target genes; thus, studies are needed to evaluate miR with solid evidence from past studies rather than those involving unknown new target genes and pathways. In contrast, the main strengths of this study are that it provides data to indicate miR-196a as an acceptable marker and that it can be considered as a pilot study for similar studies in the future. FFPE is considered useful to evaluate the expression levels of miRs.

In conclusion, to the best of our knowledge, this is the first study to examine LNM-related miR in early-stage TSCC and also the first miR study of 'delayed' LNM of H&N cancer. In addition, our findings revealed that miR-196a-5p is a potential new biomarker for the prognosis of TSCC and our results serve as a foundation for further studies (not only fresh tissues and FFPE but also blood and saliva of preoperative and postoperative samples) to evaluate the utility of this miR in the prediction of delayed LNM during the treatment of patients with early-stage TSCC. Furthermore, the results enhanced efforts to prevent metastasis when combined with close follow-up and aggressive adjuvant therapy or END. Moreover, our data will serve as a foundation for future studies to evaluate whether miR-196a-5p can serve as a therapeutic marker for preventing metastasis.

The authors would like to thank Reika Takamatsu and Toshiyuki Nishihira (Department of Pathology and Oncology, Graduate School of Medicine, University of the Ryukyus) for the technical support.
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![ΔCq value expressions of (A-E) 5 candidate miRs \[(A) miR-196a-5p, (B) miR-196b, (C) miR-10a, (D) miR-10b, and (E) miR-196a-3p\] in early-stage TSCC tissues and paired adjacent normal tissues. P-values of miR-196a-5p, miR-196b, miR-10a, miR-10b, and miR-196a-3p were \<0.001, \<0.001, \<0.001, \<0.001, and 0.003 respectively. miR, microRNA; TSCC, tongue squamous cell carcinoma.](ol-15-02-2349-g00){#f1-ol-0-0-7562}

![Association of ΔΔCq value regulation of miR-196a-5p expression with (A) overall survival, (B) local recurrence-free survival, (C) lymph node metastasis-free survival, (D) distant metastasis-free survival, and (E) disease-free survival. Kaplan-Meier analysis (cut-off: The median ΔΔCq value) indicated that patients with relatively low ΔΔCq value regulation levels of miR-196a-5p experienced significantly shorter lymph node metastasis-free survival than those with high ΔΔCq value regulation levels (P=0.0079, log-rank test). Overall survival, local recurrence-free survival, distant metastasis-free survival, and disease-free survival showed no significant differences between low and high groups of miR-196a-5p regulations (P=0.6205, P=0.0502, P=0.5382, and P=0.1049, respectively, log-rank test).](ol-15-02-2349-g01){#f2-ol-0-0-7562}

![Receiver operating characteristic analysis of ΔΔCq values of miR-196a-5p to confirm the prognostic marker in early-stage tongue squamous cell carcinoma. (A) ΔΔCq values revealed that miR-196a-5p levels had a P-value of 0.0025, an AUC of 0.740, and a cut-off value of −0.875 to distinguish lymph node metastasis. (B) ΔΔCq values revealed that miR-196a-5p levels had a P-value of 0.0133, an AUC of 0.718, and the cut-off value of −0.74 to distinguish YK grade 4C-4D from YK grade 1--3. AUC, area under the curve.](ol-15-02-2349-g02){#f3-ol-0-0-7562}

###### 

Clinicopathological characteristics of our patients (n=50).

  Subgroups                n (%)
  ------------------------ ----------
  Age                      
    \<60                   21 (42)
    ≥60                    29 (58)
  Sex                      
    Male                   24 (48)
    Female                 26 (52)
  Clinical T stage         
    I                      32 (64)
    II                     18 (36)
  Local recurrence         
    Yes                      4 (8)
    No                     46 (92)
  Delayed LNM              
    Yes                    17 (34)
    No                     33 (66)
  Distant metastasis       
    Yes                      3 (6)
    No                     47 (94)
  Histological grade       
    G1/well                31 (62)
    G2/moderate            16 (32)
    G3/poor                  1 (2)
    G4/undifferentiated      0 (0)
    Unknown                  2 (4)
  Mode of tumor invasion   
    1--3                   39 (78)
    4C-4D                  11 (22)
  Depth of tumor           
    \<5 mm                 46 (92)
    5 mm ≤ and \<10 mm       4 (8)
    ≥10 mm                   0 (0)
  Lymphatic invation       
    Yes                      6 (12)
    No                     43 (86)
    Unknown                  1 (2)
  Venous invasion          
    Yes                      5 (10)
    No                     45 (90)
  Neural infiltration      
    Yes                    5 (10)
    No                     44 (88)
    Unknown                  1 (2)
  Smoking                  
    Current or past        19 (38)
    Never                  31 (62)
  Alcohol intake           
    Current or past        22 (44)
    Never                  25 (50)
    Unknown                3 (6)

n, number of cases; LNM, lymph node metastasis.

###### 

Association of miR levels and clinicopathological characteristics of our patients (n=50).

  Subgroup                 miR-10a                miR-10b                   miR-196a-5p              miR-196a-3p    miR-196b                 
  ------------------------ ---------------------- ------------------------- ------------------------ -------------- ------------------------ --
  Age                                                                                                                                        
    \<60                   1.420±1.330            0.542 (−2.02--3.695)      −2.027±1.819             0.445±2.144    −2.091±1.744             
    ≥60                    1.21±0.993               0.985 (−2.135--2.245)   −1.845±1.999             1.512±2.541    −1.696±2.149             
    P-value                0.5250                 0.1628                    0.7423                   0.1247         0.4921                   
  Gender                                                                                                                                     
    Male                   1.181±1.303            0.345±1.253               −2.101±2.043             1.128±2.545    −2.102±1.628             
    Female                 1.406±0.976            1.058±1.146               −1.756±1.799             1.005±2.345    −1.640±2.267             
    P-value                0.4904                 **0.0410**                0.5288                   0.8603         0.4665                   
  Clinical stage                                                                                                                             
    I                      1.301±1.245            0.678±1.255               −1.714±1.690             1.032±2.603    −1.443±1.647             
    II                     1.292±0.955            0.784±1.246               −2.290±2.249             1.121±2.121    −2.606±2.331             
    P-value                0.9793                 0.7737                    0.3112                   0.9017         **0.0451**               
  Local recurrence                                                                                                                           
    Yes                    0.813±0.760            0.711±1.092               0.265±0.554              3.783±3.902    −0.271±1.147             
    No                     1.340±1.162            0.716±1.263               −2.112±1.866             0.828±2.154    −2.000±1.984             
    P-value                0.3805                 0.9931                    **0.0153**               **0.0175**     0.0942                   
  Delayed LNM                                                                                                                                
    Yes                    1.199±1.164            0.545±1.514               −2.995±1.452             0.011±1.668    −2.224±1.979             
    No                     1.349±1.140            0.804±1.088               −1.369±1.896             1.606±2.583    −1.666±1.982             
    P-value                0.6636                 0.4897                    **0.0033**               **0.0114**     **0.3349**               
  Distant metastasis                                                                                                                         
    Yes                    2.065 (−0.677--2.69)   0.905±0.587               −2.254±0.287             0.882±1.055    −0.645±0.420             
    No                     1.165 (−0.655--4.58)   0.704±1.273               −1.900±1.967             1.076±2.486    −1.939±2.016             
    P-value                0.7131                 0.7882                    0.2976                   0.8946         **0.0059**               
  Histological grade                                                                                                                         
    G1/well                1.178±1.190            0.642±1.063               −1.529±1.854             1.359±2.821    −0.96 (−7.03--2.27)      
    G2/moderate            1.455±1.103            0.95±1.461                −2.479±1.983             0.495±1.602    −2.825 (−5.155--0.81)    
    G3/poor                1.165                  1.29                      −2.195                   0.755          −3.21                    
    Unknown                1.962±1.028            −0.285±2.453              −3.402±1.446             1.202±1.156    −2.805 (−4.6--1.01)      
    P-value                0.7321                 0.5453                    0.2774                   0.7249         0.5092                   
  Mode of tumor invasion                                                                                                                     
    1--3                   1.283±1.175              0.92 (−2.02--3.695)     −1.584±1.838             1.285±2.619    −1.697±2.059             
    4C-4D                  1.349±1.051            0.745 (−2.135--1.45)      −3.12±1.727              0.282±1.319    −2.447±1.615             
    P-value                0.8679                 0.2511                    **0.0168**               0.0918         0.2716                   
  Depth of tumor                                                                                                                             
    \<5 mm                 1.289±1.081            0.785±1.069               −1.832±1.941             −1.831±2.018   1.081±2.483              
    5 mm ≤ and \<10 mm     1.406±1.905            −0.078±2.658              −2.955±1.209             −2.211±1.676   0.876±1.751              
    P-value                0.8457                 0.5638                    0.2633                   0.7173         0.8730                   
  Lymphatic invasion                                                                                                                         
    Yes                    1.364±1.347            0.823±1.051               −1.039±1.308             1.343±3.713    −1.643±1.413             
    No                     1.315±1.125            0.672±1.273               −2.028±1.977             0.955±2.224    −1.914±2.075             
    Unknown                0.175                  1.955                     −2.63                    4.07           −0.935                   
    P-value                0.6153                 0.5878                    0.4685                   0.4339         0.8563                   
  Venous invasion                                                                                                                            
    Yes                    1.199±0.569            0.066±1.303               −2.725±1.534             0.354±0.720    −2.802±2.230             
    No                     1.309±1.189            0.788±1.226               −1.832±1.939             1.143±2.530    −1.757±1.950             
    P-value                0.8396                 0.2199                    0.3264                   0.1278         0.2677                   
  Neural infiltration                                                                                                                        
    Yes                    0.67±0.630             −0.002±1.318              −2.995 (−6.485--3.285)   1.005±2.367    −1.651±2.596             
    No                     1.395±1.164            0.769±1.221               −2.025 (−4.735--0.725)   1.003±2.435    −1.907±1.953             
    Unknown                0.175                  1.955                     −2.63                    4.07           −0.935                   
    P-value                0.2493                 0.2564                    0.6001                   0.4640         0.8660                   
  Smoking                                                                                                                                    
    Current or past        1.120±1.008            0.235±1.027               −2.463±1.949             1.599±3.009    −1.575 (−5.195--0.185)   
    Never                  1.407±1.215            1.011±1.281               −1.590±1.836             0.736±1.956    −1.36 (−7.03--2.27)      
    P-value                0.3931                 **0.0303**                0.1175                   0.2749         0.5622                   
  Alcohol intake                                                                                                                             
    Current or past        1,353±1.340            0.383±1.270               −2.071±1.944             1.306±2.819    −1.23 (−5.195--0.185)    
    Never                  1.310±0.998            1.050±1.130               −1.728±1.851             0.851±2.068    −1.49 (−7.03--2.27)      
    Unknown                0.794±0.741            0.371±1.611               −2.434±2.704             1.067±2.707    −4.385 (−4.51--0.4325)   
    P-value                0.7335                 0.1635                    0.7459                   0.8194         0.5670                   

P\<0.05 indicated statistically significance. Bold values means the significant P-values (\<0.05). n=50. The number of subgroups is described in [Table I](#tI-ol-0-0-7562){ref-type="table"}. The expression value of each miR is used ΔΔCq value. A Gaussian distribution of each group was tested by Shapiro-Wilk test. The homogeneity of the variances was confirmed by Levene test. For data with a Gaussian distribution, the difference between the two groups was demonstrated by Student\'s t-test or Welch\'s t-test depending on the homogeneity of the variances. For data that did not conform to a Gaussian distribution, the Mann-Whitney test was applied to compare the samples. When analyzing more than two subgroups, one-way ANOVA or Kruskal-Wallis test was used to test whether the data conformed to a Gaussian distribution. All statistical analyses were performed using the JMP software (JMP Version Pro 12; SAS Institute Inc., Cary, NC, USA). miR, micro RNA; n, number of cases; LNM, lymph node metastasis.

###### 

Association between microRNA-196a-5p ΔΔCq value regulation and subgroups (n=50).

                           Case number of groups         
  ------------------------ ----------------------- ----- -----------
  Age                                                    
    \<60                   10                      11    1.000
    ≥60                    15                      14    
  Gender                                                 
    Male                   12                      12    1.000
    Female                 13                      13    
  Clinical stage                                         
    I                      18                      14    0.377
    II                       7                     11    
  Local recurrence                                       
    Yes                      4                       0   0.110
    No                     21                      25    
  Delayed LNM                                            
    Yes                      4                     13    **0.016**
    No                     21                      12    
  Distant metastasis                                     
    Yes                      1                       2   1.000
    No                     24                      23    
  Histological grade                                     
    G1/well                17                      14    0.653
    G2/moderate              8                       8   
    G3/poor                  0                       1   
    Unknown                  0                       2   
  Mode of tumor invasion                                 
    1--3                   22                      17    0.171
    4C-4D                    3                       8   
  Depth of tumor                                         
    \<5 mm                 24                      22    0.609
    5 mm ≤ and \<10 mm       1                       3   
  Lymphatic invasion                                     
    Yes                      4                       2   0.667
    No                     21                      22    
    Unknown                  0                       1   
  Venous invasion                                        
    Yes                      2                       3   1.000
    No                     23                      22    
  Neural infiltration                                    
    Yes                      2                       3   0.667
    No                     23                      21    
    Unknown                  0                       1   
  Smoking                                                
    Current or past          9                     10    1.000
    Never                  16                      15    
  Alcohol intake                                         
    Current or past        11                      11    1.000
    Never                  13                      12    
    Unknown                1                       2     

P\<0.05 indicated statistically significance. Bold values means the significant P-values (\<0.05). n=50. Differences in the patient numbers between the high ΔΔCq value regulation group and the low ΔΔCq value regulation group were evaluated by a two-tailed Fisher\'s exact test. All statistical analyses were performed using the JMP software (JMP Version Pro 12; SAS Institute Inc., Cary, NC, USA). n, number of cases; LNM, lymph node metastasis.
